Podcasts about Gynecologic oncology

Endometrial cancer is the most common gynecologic cancer in the United States and the fourth most common cancer affecting women. One of its most important warning signs – abnormal vaginal bleeding or spotting – is something many women experience and may dismiss. While survival rates exceed 95%, both overall incidence and mortality rates are rising. In this episode, we speak with Ursula A. Matulonis, MD, chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, about the symptoms of endometrial cancer, the role family history plays in risk, and the lifestyle habits that may help lower your chances of developing the disease. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Lauren Summers Show Notes: Lauren Summers Guest: Ursula A. Matulonis, MD See omnystudio.com/listener for privacy information.

Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics: Introduction (0:00) Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30) Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39) Tolerability and Other Practical Considerations with Novel Investigational ADCs in Advanced Gynecologic Cancers — Dr Monk (1:04:58) CME information and select publications

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis was joined by Meghan E. Shea, MD, an attending medical oncologist and ambulatory medical director and disease program leader for medical oncology at Beth Israel Deaconess Medical Center in Boston. Together, they explored the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and antibody-drug conjugates (ADCs) across disease settings.Dr Shea opened by addressing the epidemiology of cervical cancer, noting that despite decades of progress, rates are now plateauing and rising among women under 50 years of age. She identified 3 interrelated drivers of this trend: declining rates of routine gynecologic screening, inconsistent uptake of human papillomavirus (HPV) vaccination, and persistent high-risk HPV infections, particularly HPV 16 and 18, which are responsible for most cases. The conversation then turned to the effect of immunotherapy on cervical cancer treatment. Dr Shea traced the evolution of pembrolizumab (Keytruda) from its initial 2018 approval as a single agent in recurrent/metastatic disease to its more recent integration into the frontline setting. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated that adding pembrolizumab to standard weekly cisplatin-based chemoradiation significantly improved outcomes for patients with locally advanced disease. Although responses to immunotherapy, when they occur, are often durable, Dr Shea acknowledged that response rates remain lower than anticipated for a virally driven malignancy, underscoring the need for novel combinations and a deeper understanding of resistance mechanisms. Drs Matulonis and Shea both agreed that immunotherapy combined with ADCs represents one of the most compelling directions for the field, with phase 2 data for sacituzumab tirumotecan plus pembrolizumab generating interest ahead of anticipated phase 3 results.On the ADC front, Dr Shea reviewed the 2 agents in this class that are currently FDA-approved for cervical cancer. Tisotumab vedotin-tftv (Tivdak) offers the advantage of biomarker-independent use, though its requirement for ophthalmologic monitoring at every treatment visit creates real-world access challenges outside major academic centers. Trastuzumab deruxtecan-nxki (Enhertu), approved in the HER2 immunohistochemistry 3+ setting based in part on the results of the phase 2 DESTINY-PanTumor02 trial (NCT04482309), has generated robust response rates but is most likely to benefit patients with adenocarcinoma. Dr Shea also highlighted additional targets under investigation, including Trop-2, Nectin-4, and B7-H4, with multiple phase 3 trials ongoing in both the frontline and recurrent settings.The discussion closed with a look at the locally advanced disease landscape, where the NRG Oncology cooperative group is conducting a phase 3 trial to evaluate whether integrating the neoadjuvant carboplatin/paclitaxel regimen from the INTERLACE trial (NCT01566240) with the pembrolizumab-based regimen from KEYNOTE-A18 can further improve outcomes and reduce the morbidity associated with brachytherapy. Dr Shea expressed optimism about this question, citing preliminary experience suggesting that neoadjuvant chemotherapy may reduce the need for invasive radiation techniques.

Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics: Introduction (0:00) Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59) Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53) Other Novel Agents and Strategies for Advanced Ovarian Cancer — Dr Olawaiye (46:40) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced Ovarian Cancer — Dr Konecny (1:19:11) CME information and select publications

Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25:18) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy in Advanced EC — Dr Salani (59:02) CME information and select publications

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O'Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O'Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this episode, Dr Matulonis was joined by Elizabeth H. Stover, MD, PhD, a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School. Together, they explored the biology and therapeutic relevance of the RAS/MAP kinase pathway in gynecologic cancers. Dr Stover began by explaining that the RAS/MAP kinase pathway is a well-established oncogenic signaling cascade that regulates cancer cell proliferation, survival, and invasion. Advances in drug development are now making it possible to target multiple points along this pathway, including RAS itself, once considered “undruggable.”Drs Matulonis and Stover emphasized that RAS/MAP kinase pathway alterations are relatively common across gynecologic malignancies, occurring in at least 20% of cases overall. Certain disease subtypes have particularly high prevalence, including low-grade serous ovarian cancer, mucinous ovarian cancer, and subsets of endometrial and cervical cancers. Clinically, activation of this pathway is generally associated with more aggressive disease and reduced sensitivity to conventional chemotherapy, although nuances exist. The conversation also explored emerging therapeutic strategies targeting this pathway. Early developmental success with MEK inhibitors—such as trametinib (Mekinist), selumetinib (Koselugo), and binimetinib (Mektovi)—has translated to meaningful clinical benefit, particularly in low-grade serous ovarian cancer. More recently, combination approaches have shown promise, including the dual RAF/MEK inhibitor avutometinib paired with the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack). This combination addresses adaptive resistance mechanisms and has generated improved response rates and disease control, leading to its May 2025 FDA approval in this setting.Looking ahead, Dr Stover highlighted the development of direct RAS inhibitors as one of the most exciting advances in oncology. Dr Stover concluded by outlining key areas of ongoing research, including understanding differential sensitivity across tumor subtypes, identifying mechanisms of resistance, and optimizing combination strategies. 

This content has been funded by AstraZeneca, and is intended for healthcare professionals. The content in this podcast is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment, nor to promote any specific product or therapy.  The guests have been compensated by AstraZeneca for their participation. The views expressed are their own and do not necessarily reflect those of the AMJ or AstraZeneca. If you choose to act on information discussed here, you do so at your own discretion. Description: As homologous recombination deficiency (HRD) testing becomes increasingly embedded in ovarian cancer pathways, clinicians need clear, operational guidance. This episode brings together expert perspectives on selecting tests, understanding outputs, and integrating results into guideline-aligned care.  Learn: ·       HRD basics in plain language: what you're measuring and why ·       Test selection and reporting nuances that affect downstream decisions ·       Workflow design across oncology, pathology, and genetics ·       Applying results to maintenance strategies and patient conversations  Speakers: 1.     Rebecca Arend, Associate Director for Clinical Research, UAB O'Neal Comprehensive Cancer Center; Endowed Professor of Gynecologic Oncology, University of Alabama, USA. 2.   Thomas Krivak, Director, Division of Gynecologic Oncology; Chief Surgeon, West Penn Hospital, USA. 3.    Bhavana Pothuri, Gynecologic Oncologist, NYU Langone Health; Associate Professor, Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, USA.

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancerEditorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selectionHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAAlexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAJose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Katharine M. Esselen, MD, MBA. Dr Esselen is an attending gynecologic oncologist at Beth Israel Deaconess Medical Center and an assistant professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School in Boston. Drs Matulonis and Esselen explored the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes. Dr Esselen, whose research focuses on patient-centered outcomes and value-based care, highlighted that financial toxicity extends beyond direct medical costs to include indirect burdens such as lost wages, childcare needs, transportation, and basic living expenses. To address these challenges, Dr Esselen and her colleagues developed a financial navigation program at Beth Israel Deaconess Medical Center. This initiative includes systematic screening for financial concerns and dedicated support from a financial navigator who connects patients with resources such as insurance optimization, transportation assistance, and financial aid programs. Implementation of this program significantly increased identification of at-risk patients and improved access to supportive services.Importantly, Drs Matulonis and Esselen emphasized that financial toxicity is not only a quality-of-life issue but also a clinical one. Studies show that patients experiencing high financial burden are more likely to delay or forgo care and less likely to adhere to prescribed treatments, which may ultimately affect survival outcomes. Drs Matulonis and Esselen concluded the discussion by outlining the steps that can be taken to reduce financial burden on patients, underscoring the need for proactive screening, multidisciplinary support, and systemic change.

Breast cancer and its risk can dramatically disrupt hormones and often trigger early or surgical menopause, yet menopause care is still too often treated as an afterthought. In this episode, Rachel Frankenthal, PA-C and gynecologic oncology specialist, makes the case that menopause should be a non-negotiable part of every cancer care plan from the very beginning. She explores how survivors and previvors can navigate hormonal changes, manage menopause safely, and protect long-term gynecologic health. From understanding genetic risk and prevention options to taking control of your body and choices, Rachel offers clear, practical guidance and expert strategies to help women feel empowered, informed, and confident in advocating for care that addresses their whole health, not just the cancer.

 Dr.Sabhyata Gupta | Chairperson, Gynae-Cology and Gynaec Oncology, Medanta-The Medicity, Gurgaon, ranked as the top private hospital in India  Dr. Sabhyata Gupta is the Chairperson of Gynaecology and Gynae-Oncology at Medanta, Gurugram, and a pioneering figure in her field.She is notably the first gynecologist in India to perform robotic gynaecological surgery for both cancerous and benign conditions.With extensive expertise in robotic surgery, gynaec oncology, colposcopy, advanced gynaec laparoscopy, and hysteroscopy, Dr. Gupta is a leader in providing cutting-edge treatments for women's health.Her qualifications include an MD in Gynecology, specialized training in Robotic Gynaecological Surgery, a Diploma in Gynaecological Endoscopic Surgery, and advanced training in uro-gynaecological oncology.She has also completed the Indo-German Training Course in Advanced Endoscopic Surgery in Gynecology.Dr. Gupta has received numerous accolades, including the prestigious ‘Arch of Excellence Award (Medicare)' at the All India Achievers' Conference in 2009.She is an esteemed member of several renowned organizations, including the International Gynaecological Cancer Society, the European Society of Gynaecological Oncology, the Federation of Obstetrics & Gynaecological Societies of India, and the Indian Medical Association.Specializing in Gynecologic Oncology, Dr. Gupta possesses profound expertise in a wide array of procedures such as:Robotic Gynecological SurgeryAdvanced Gynecological LaparoscopyHysteroscopyColposcopyWAwards & Recognitions Dr. Sabhyata Gupta has received numerous awards for her work and contribution to Medical Science. The most remarkable awards are-She won the Bharat Jyoti Award from the “India International Friendship Society” in Delhi in 2009.In 2009, she was facilitated with the Bharat Excellence Award & Gold Medal by the “Friendship Forum of India”, in Delhi.In the same year itself, she was conferred with the Gold Medal for the Rising Personalities of India by “The International Penguin Publishing House” in Delhi.She also won the Gold Award in the category Pride of India from the house of “Friendship Forum Of India” in Delhi in 2009.Last but not the least, she won the Arch of Excellence Award (Medicare) at the All India Achievers conference in Delhi in 2009.  

Send us Fan MailPaper Discussed in this AI Journal Club:From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging: A Systematic Review in Gynecologic Oncology. Innocenzi C, Pavone M, Seeliger B, et al. Diagnostics 2026.Episode Summary:In this journal club deep dive, we explore a groundbreaking 2026 systematic review that challenges the traditional intraoperative frozen section. We examine how hyperspectral and multispectral imaging are fundamentally reshaping the operating room by giving surgeons real-time, molecular-level vision. What happens when we can see beyond the visible spectrum, and how do we navigate the philosophical boundary between human surgical intuition and artificial intelligence?In This Episode, We Cover:• The End of the "Frozen Section" Waiting Game: Why current intraoperative pathology wastes precious surgical time and how "optical biopsies" provide cellular-level insight without the need for tissue contact, contrast agents, or freezing.• The Science of the Spectral Fingerprint: Moving beyond standard RGB monitors that limit what surgeons can see. How malignant tissues interact with light—through refraction, scattering, absorption, and fluorescence—to create unique optical signatures that our naked eyes completely miss.• Entering the Hypercube: How the 3D data sets of spectral imaging are captured: ◦ Spatial & Spectral Scanning: High-resolution methods that unfortunately struggle with breathing patients, making them susceptible to motion artifacts. ◦ Snapshot Technology: The real-time, video-rate method that balances spatial and spectral resolution for live clinical use.• Clinical Showdowns - Cervical and Ovarian Cancer: ◦ Cervical Neoplasia: How multispectral imaging tracks the dynamic whitening of tissue following acetic acid application, plummeting false-diagnostic rates to an astonishing 1.7% compared to the 20-24% error rates of traditional methods. ◦ Ovarian Cancer: The massive hurdle of surgical blood acting as an "optical sink" that confuses sensors by causing spatial heterogeneity, and how mathematical normalization techniques correct these specific errors. ◦ The Falloposcope: A look at miniaturized technology safely navigating the fallopian tubes, combining optical coherence tomography (OCT) and multispectral imaging to detect early-stage cancers right where they originate.• The "Black Box" and Spurious Correlations: Why feeding complex hypercube data into AI models (like CNNs and Random Forests) can be dangerous if the data sets are unbalanced. If an algorithm learns to diagnose cancer based on a spurious correlation like the glare of an OR light rather than actual biomolecular tumor markers, it will fail in new environments. We discuss the absolute necessity of Explainable AI (XAI) so surgeons can trust the biological plausibility of the machine's decisions.Key Takeaway: The integration of hyperspectral and multispectral imaging serves as a real-time optical biopsy, offering incredible sensitivity for detecting malignancies. By pairing these tools with transparent, explainable AI, we are standing on the precipice of a new era that will drastically improve patient outcomes and force us to redefine the future of surgical intuitionSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

In an illuminating discussion, gynecologic oncologist Noah Goldman, MD, discusses the comprehensive scope of his practice at Penn Medicine Princeton Health, including the types of cancers he treats, and expands upon the known benefit of the HPV vaccine, the mysteries of screening for endometrial and ovarian cancers, and the promise of being attentive to one's own body when things seem awry.  Learn more about Noah Goldman, MD, MBA  

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Susana M. Campos, MD, MPH. Dr Campos is the clinical director and director of Educational Initiatives for the of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, and an institute physician and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Drs Matulonis and Campos discussed the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.According to 2026 estimates from the American Cancer Society, approximately 13,400 new cases of invasive cervical cancer will be diagnosed in the United States, with roughly 4200 deaths. Although incidence has declined over time due to human papillomavirus (HPV) vaccination and screening efforts, rates have plateaued, and the disease burden remains substantial, particularly among women aged 35 to 64 years. Dr Campos noted that approximately half of cases occur in women younger than 50 years of age, and about 20% are diagnosed in women older than 65 years of age.Dr Campos reviewed common presenting symptoms, including abnormal vaginal bleeding, intermenstrual or postmenopausal bleeding, abnormal discharge, pelvic pain, and, in advanced cases, urinary symptoms or leg swelling. She explained that diagnosis begins with pelvic examination and cervical cytology or HPV testing, followed by colposcopy and biopsy when indicated. Although cervical cancer remains one of the few malignancies that is clinically staged, imaging modalities, such as MRI, CT, and PET scans, are critical to accurately defining disease extent, they underscored. Moreover, the discussion highlighted transformative advances in locally advanced disease. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated improved progression-free and overall survival with the addition of pembrolizumab (Keytruda) to standard chemoradiation, establishing a new standard for high-risk patients, Campos stated. Similarly, the phase 3 INTERLACE trial (NCT01566240) showed that short-course induction chemotherapy with carboplatin and paclitaxel before chemoradiation improved long-term outcomes. Campos forecasted that ongoing studies, including the phase 3 NRG-GY037 trial (NCT07061977), may integrate these approaches and further refine optimal treatment sequencing.Lastly, Drs Matulonis and Campos highlighted the expanding therapeutic arsenal in the recurrent and metastatic setting. Campos noted how antibody-drug conjugates, such as tisotumab vedotin-tftv (Tivdak) and fam-trastuzumab deruxtecan-nxki (Enhertu), have demonstrated meaningful activity, particularly in biomarker-selected populations. Campos added that investigational strategies targeting TROP2, such as sacituzumab govitecan-hziy (Trodelvy), represent additional promising avenues.Despite these advances, both experts emphasized that prevention remains paramount. Widespread uptake of HPV vaccination, including the 9-valent vaccine, as well as adherence to routine cervical screening, are essential to reducing the long-term burden of this largely preventable disease.

Editor's Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to discuss the groundbreaking research and clinical trials shaping the future of gynecologic cancer care. The panel explores innovations in immunotherapy, investigator-initiated trials, survivorship and symptom science, while highlighting efforts to expand access and diversity in clinical research across Chicago and the surrounding suburbs.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery• Daniela E. Matei, MD, Diana, Princess of Wales Professor of Cancer Research and Chief of Reproductive Science in the Departments of Obstetrics and Gynecology and Hematology and Oncology• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director• Emily M. Hinchcliff, MD, Assistant Professor of Gynecologic Oncology and Program Director of the OB-GYN Residency Program

This week's Health Matters radio show and podcast features an important and timely conversation focused on Gynecologic Oncology at Aultman, highlighting advances in care, patient advocacy, and the multidisciplinary support available to women facing complex cancer diagnoses. https://www.medshoprx.com/blog/health-matters-radio-gynecologic-oncology-at-aultman

This episode brings together the science, the medicine, and the lived experience behind BRCA mutations.  Emily Goldberg, JScreen's Director of Genetic Counseling Services, breaks down what these mutations are, how they're inherited, and what the actual cancer risks look like. Dr. Melissa Frey, a GYN oncologist at Cornell who works closely with high-risk families, walks us through what happens after someone tests positive — from screening to risk-reducing surgeries to the big conversations around fertility and timing. We also hear from Heather Boussi, who shares her powerful story of living with both BRCA1 and BRCA2 mutations. She talks about diagnosis, surveillance, surgeries, and how this all shaped her family-building decisions. Lastly, we look at what BRCA means for men, how that journey differs, and why PGT can still be an option. If you or someone you love is navigating this, we close with places to turn for support: JScreen, Sharsheret, I Was Supposed To Have A Baby, and Stardust (links below). It's a mix of expertise, honesty, and heart — the kind of conversation so many people wish they had heard earlier, especially when faced with such difficult decisions.  Note: This episode is the 4th of a series of 5 that we are collaborating on with Jscreen in 2025.  Take a look at our previous three episodes here : Episode 157: Introduction to Genetics and Infertility Episode 166: Fragile X Syndrome: A Silent Factor in Infertility Episode 185: It's Not Just Her: Male Factor Fertility and Genetics Uncovered Resources: Genetics and Personalized Cancer Prevention Program Facing Our Risk Empowered (FORCE) Jewish Fertility Foundation Stardust Foundation Sharsheret JScreen More about Emily Goldberg: Emily Goldberg serves as the Director of Genetic Counseling Services at jscreen, where she is dedicated to helping individuals understand and manage their genetic health. With dual bachelor's degrees in biology and psychology from Brandeis University and a master's degree in Human Genetics from Sarah Lawrence College, Ms. Goldberg has been a certified genetic counselor since 2011. Prior to joining jscreen, she worked at Montefiore Medical Center in the Bronx, specializing in prenatal and cancer genetics. In addition to her role at jscreen, Ms. Goldberg is committed to education, serving as an Instructor at the Albert Einstein College of Medicine and adjunct faculty at Sarah Lawrence College, where she teaches and mentors future genetic counselors. Her expertise and dedication make her a key member of the jscreen team. Connect with JScreen: - visit their website here - check out their Instagram   More about Melissa Frey, MD: Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine / NewYork Presbyterian Hospital. Dr. Frey's clinical care and research focus on the management of individuals with hereditary cancer syndromes (e.g. BRCA1, BRCA2, Lynch syndrome) and strong family history of breast and gynecologic cancers. She performs gynecologic cancer risk-reducing surgeries and is the principal investigator on several large trials aimed at cancer prevention among high-risk individuals. Dr. Frey has presented her research at national and international meetings and has more than 130 publications in peer-reviewed scientific journals. Connect with Dr. Melissa Frey: - check out her Instagram - view the Genetics and Personalized Cancer Prevention Program website   More about Heather Boussi :  Heather grew up in Westchester, NY and now lives in Englewood, NJ with her husband and three children. Her personal experience with hereditary cancer risk and genetic testing has made her a passionate advocate for awareness, education, and empowerment in women's health. Grounded in faith and family, Heather shares her story to help others approach life's challenges with strength, perspective, and gratitude. Connect with Heather: - check out Heather's Instagram   Connect with us: -Check out our Website -Follow us on Instagram and send us a message -Watch our TikToks -Follow us on Facebook -Watch us on YouTube -Connect with us on LinkedIn

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this episode, Dr Matulonis sat down with guest Panagiotis (Panos) A. Konstantinopoulos, MD, PhD, to discuss the different subtypes of endometrial cancer and treatment developments for this disease. Dr Konstantinopoulos is the director of Translational Research in the Division of Gynecologic Oncology, the director of the Mellen and Eisenson Family Center for BRCA and Related Genes, and the Velma Eisenson Chair for Clinical and Translational Research at Dana-Farber Cancer Institute; as well as a professor of medicine at Harvard Medical School. Drs Matulonis and Konstantinopoulos explained that patients with mismatch repair–deficient (dMMR) tumors substantially benefit from a decreased risk of progression or death when immunotherapy is added to standard therapy. They noted that immunotherapy appears important for the management of dMMR tumors, even those in earlier stages or in patients who have no measurable disease remaining after surgery. For MMR-proficient (pMMR) tumors, Drs Matulonis and Konstantinopoulos highlighted that PD-1 blockade combined with chemotherapy improves survival vs chemotherapy alone, but that this benefit is not as substantial as that seen in dMMR disease. Crucially, they reported that if a pMMR tumor has no measurable disease after surgery, adding immune checkpoint blockade does not appear beneficial. They stated that tailored treatment approaches are key for managing pMMR disease subtypes. They added that hormonal therapy may be used upfront for slow-growing, estrogen receptor–positive metastatic disease. They continued by saying that DNA damage and replication stress are critical targets, particularly in p53-mutated tumors, like uterine serous cancers. Furthermore, they stressed that although the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) is highly effective in HER2-positive tumors, treatment with this agent requires monitoring for toxicities, including interstitial lung disease and decreased ejection fraction.

Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. Dr. Brian Slomovitz discusses how lifestyle interventions and emerging therapies may reduce cancer recurrence. He's the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to explore the innovative role of robotic surgery in cancer care. The discussion highlights how robotic technology is improving outcomes for patients with gynecologic cancers through minimally invasive techniques, enhanced precision and interdisciplinary collaboration.The panel covers advancements in robotic systems, patient populations who benefit most from this approach, including those with high BMI, complex surgical histories, and fertility concerns, as well as the future of surgical innovation at Northwestern Medicine.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery.• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director.• Jenna Z. Marcus, MD, Associate Professor of Gynecologic Oncology, Director of Robotic Simulation and Associate Fellowship Program Director.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this inaugural episode, Dr Matulonis welcomed guest Taymaa May, MD, MSc, to discuss advances in gynecologic cancer surgery. Dr May is the director of Ovarian Cancer Surgery in the Division of Surgical Oncology at the Brigham and Women's Hospital in Boston, as well as an associate professor at Harvard Medical School. One of the biggest transformative changes in the field has been the introduction of minimally invasive surgery using laparoscopic and robotic platforms, Dr May emphasized. This allows for precise cancer staging surgery and faster patient recovery without compromising cancer outcomes, she noted. Complementing this has been the innovation of sentinel lymph node mapping, which uses technology, such as an infrared dye, to precisely identify and remove only the necessary lymph nodes. This offers equal staging precision and reduces patient morbidity with lower extremity lymphedema, a common adverse effect associated with older, extensive lymph node dissections, according to Dr May. The experts stressed the importance of consulting a gynecologic oncology surgeon, as national studies indicate that patients assessed and operated on by these specialists achieve the most optimal clinical outcomes. For advanced ovarian cancer, which often requires complex multivisceral resection to achieve optimal tumor removal, Dr May explained that surgical innovations are used to enhance recovery. For example, she noted that fluorescence angiography assesses blood flow in fresh bowel sutures intraoperatively, which helps ensure proper healing and minimizes complications. In cervical cancer, Dr May said that radical trachelectomy offers a safe, fertility-preserving option for young patients with suitable tumors. Furthermore, when determining treatment for patients with advanced ovarian cancer, she emphasized that personalization is key. Ultimately, Drs Matulonis and May reported that integrating surgical innovation into gynecologic cancer treatment protocols ensures optimal recovery, which is critical for patients to start subsequent treatments, like chemotherapy, on time.

In today's episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT05403554) investigating NI-1801 in patients with heavily pretreated, mesothelin-expressing platinum-resistant epithelial ovarian cancer. Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecologic Oncology Clinical Research at Siteman Cancer Center in Saint Louis, Missouri, discussed the anticipation for findings from a multi-omic analysis of the phase 3 AtTEnd/ENGOT-EN7 trial (NCT03603184) of atezolizumab in patients with endometrial cancer and data demonstrating that the WES-derived Aneuploidy Score may identify patients with mismatch repair–deficient endometrial cancer who derive reduced benefit from immunotherapy. Zev Wainberg, MD, the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research at UCLA, shared his anticipation for new data in gastrointestinal oncology, particularly the overall survival results from the phase 3 MATTERHORN trial (NCT04592913) of durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric and gastroesophageal cancer, which are expected to provide pivotal updates following previously reported event-free survival outcomes. Sagus Sampath, MD, an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California, highlighted the phase 2 NorthStar trial (NCT03410043) evaluating osimertinib (Tagrisso) with or without local consolidative therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).

Today, I am honored to connect with Rachel Frankenthal, a board-certified physician assistant with a master's degree in public health, specializing in gynecologic oncology. Rachel is on the staff at UCLA Health, where she treats women with gynecologic cancers and women at high risk for uterine or ovarian cancer due to genetic mutations or a strong family history.  In our discussion, we unpack GYN oncology, covering the five GYN cancers, why ovarian cancer is the silent killer, and the labs and ultrasounds to help screen for ovarian cancer. We dive into genetics, including BRCA mutations and Lynch syndrome, appropriate genetic counseling, and what Rachel considers when dealing with younger patients still at peak fertility versus older patients. We explore the importance of HRT utilization for cancer previvors, the effects of pelvic radiation, vaginal and sexual health, and what thriving looks like after cancer. Rachel shares her stepwise approach to hot flashes, and we also discuss the importance of lifestyle, bone health, and specific research on the benefits of GLP-1s for women with ovarian and endometrial cancer.  This conversation is especially relevant as we are in GYN and Ovarian Cancer Awareness Month. I look forward to having Rachel back again, hopefully later this fall, to discuss the use of hormone replacement therapy with GYN oncology survivors. IN THIS EPISODE, YOU WILL LEARN: How the lack of effective screening makes ovarian cancer hard to detect due to  How BRCA and Lynch syndrome influence cancer risk and treatment choices The benefits of HRT for cancer previvors Risks that arise from surgical menopause without sufficient or properly dosed HRT Why less than 50% of eligible women actually receive hormone therapy How pelvic radiation impacts menopause, vaginal tissue, bladder, and GI health The support that is crucial for cancer survivors after pelvic radiation Lifestyle factors to improve cancer treatment outcomes   Rachel shares her stepwise approach to managing hot flashes  What GLP-1 research reveals about reducing ovarian cancer mortality and endometrial cancer risk Bio: Rachel Frankenthal Rachel Frankenthal is a board-certified and licensed Physician Associate and Menopause Society Certified Practitioner with a Master's in Public Health. She specializes in gynecologic oncology, treating women with gynecologic cancers as well as women at high risk for uterine or ovarian cancer due to genetic mutations. Rachel has a special passion for menopause and midlife women's healthcare. She developed the menopause clinic for gynecologic cancer survivors and previvors at UCLA and has played an integral role in developing the GYN cancer survivorship program, where she teaches the weekly yoga and meditation class. Rachel lectures at UCLA and across the country on the importance of comprehensive menopause care in cancer survivorship and has created a course on hormone therapy for gynecologic cancer survivors through the Heather Hirsch Academy. In addition to being a medical practitioner, Rachel is a certified yoga and Pilates instructor, a prior Broadway performer, and an advocate for integrative, holistic health. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Rachel Frankenthal On Instagram

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Charles Dietrich, MD Associate Professor, Gynecologic Oncology, UK Markey Cancer Center and Medical Co-Director, Ovarian Cancer Screening Program Cancer Conversations Episode 67 During this episode of Cancer Conversations on Talking FACS, host Mindy McCulley sits down with Dr. Charles Dietrich, Associate Professor of Gynecologic Oncology and Medical Co‑Director of the Ovarian Cancer Screening Program at UK Markey Cancer Center.  They discuss the long‑running, free ovarian cancer screening effort across Kentucky. When discussing the Ovarian Cancer Screening program, a long-term research program, they address: who is eligible where screenings are offered how abnormal findings are managed, and barriers to participation. Dr. Dietrich reviews program outcomes — more than 50,000 women screened since 1988 with ~130 cancers detected, many at earlier stages with markedly better cure rates — and outlines future plans to refine screening with additional biochemical tests and expanded sites. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey

Shannon Miller is one of the most decorated American gymnasts in history, winning seven Olympic medals and becoming an icon of the 1990s gymnastics era. Beyond her success on the balance beam and floor, she faced one of her greatest challenges outside the gym. In 2011, Shannon was diagnosed with a rare form of ovarian cancer. After surgery and chemotherapy, she emerged cancer-free and has since dedicated herself to raising awareness about women's health. Today, Shannon will join us "On The Sidelines" to discuss her journey of resilience, reminding women to prioritize their health, and the importance of Biomarker Testing—which will be thoroughly explained by Professor and Director of Gynecologic Oncology at the James Comprehensive Cancer Center at The Ohio State University, Dr. David O'Malley.On the Sidelines is presented by OrthoCincy Orthopaedics & Sports Medicine.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company's oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today. Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in advanced ovarian cancer, and the oncological space – and ASCO 2025 itself – more generally. You can also listen to episode 185a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

I'm thrilled to sit down with Dr. Lorna Rodriguez, a medical doctor with a PhD in biochemistry and a true double doc!

Editor's choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG studyEditorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equityHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic OncologyFeaturing:V.L. Bae-Jump, University of North Carolina at Chapel Hill, Chapel Hill, NC, USABrian M. Slomovitz, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, FLCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Dr Kathleen Moore, Dr Ritu Salani, Dr Shannon Westin and moderator Dr Angeles Alvarez Secord share their perspectives and summarize recently presented data from the SGO 2025 annual meeting guiding the management of ovarian cancer. CME information and select publications here.

In today's episode, we sat down with Liliana Bustamante, MD, and Jessica Stine, MD, to discuss their experiences as women in oncology. Dr Bustamante is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute in Tampa. Dr Stine is the medical director of Gynecologic Oncology at Florida Cancer Specialists & Research Institute. In our exclusive interview, Drs Bustamante and Stine discussed their unique journeys toward choosing careers in oncology, the emotional fulfillment of treating patients with cancer, the importance of mentorship between colleagues, and the evolving nature of work-life balance. They also emphasize the importance of honesty, peer support, and self-grace in navigating oncology careers.

Drs Kathleen N Moore and Alessandro D Santin and moderator Dr David M O'Malley summarize and share their perspectives on data guiding the management of HER2-positive gynecologic cancers that were presented at the Society of Gynecologic Oncology 2025 annual meeting. CME information and select publications here.

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. David O'Malley, and Bobbie R, an ovarian cancer patient. Dr. O'Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide insight into her experience with HRD testing.   Dr. David O'Malley is a professor in the department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James.   Bobbie is a stage 3C ovarian cancer patient who lives in Rochester, New York. Bobbie is an animal rights activist, vegetarian, and exerciser who recently retired from the healthcare field, having worked as a registered nurse and owner of a healthcare staffing firm. Following her diagnosis in July of 2021, Bobbie participated in biomarker testing which indicated that she was breast cancer gene (BRCA) negative and homologous recombination deficiency (HRD) positive. After undergoing surgery and chemotherapy as first-line treatment, Bobbie's oncologist explained that she was eligible for a poly-ADP ribose polymerase (PARP) inhibitor due to her HRD status and on March 7, 2022, Bobbie started on a PARP inhibitor for maintenance treatment. As she continues treatment in 2024, Bobbie celebrates over 45 years of marriage with her husband and looks forward to traveling the United States, reading good books, and spending time with her dogs.   For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html   For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokespeople's opinions and experiences.

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.   Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care.   For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients.   Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine.   For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.

On this episode of Health 411, host Dr. Jonathan Karp and student producer chat with Dr. Mona Saleh, Gynecologic Oncologist at Capital Health.

Dr. Crane is a distinguished leader in cancer control and is passionate about her commitment to the science of better outcomes for patients and community. Her work sits at the intersection of lifestyle medicine and digital health with a goal of developing targeted interventions, utilizing digital biomarkers to deliver the right intervention, at the right time to the right person. She received her Ph.D. from the University of Arizona and is an R25 Transdisciplinary Research on Energetics and Cancer (TREC) NCI Fellow.Dr. Crane was recruited to Sylvester Comprehensive Cancer Center to co-lead the Cancer Control Research Program and direct the Lifestyle Medicine, Prevention and Digital health initiative. She serves on the University of Miami IRB's consent to contact committee as the Sylvester representative for cancer-related studies and is an appointed cabinet member to the Executive Dean for Research of the Miller School of Medicine. As the population science representative, she serves on the Gynecologic Oncology and Lymphoma site disease groups and works with clinical and research faculty members. She was recently appointed the Vice-Chair for NRG Oncology NCORP Cancer Prevention and Control Committee.Dr. Crane joined Sylvester from the College of Nursing, Biobehavioral Health Sciences Division, at the University of Arizona in Tucson, where she served as co-lead of the Behavioral Measurement and Interventions Shared Resource at the University of Arizona Cancer Center. She also held joint appointments in the Department of Nutrition Sciences, Data Science Institute, and Mel and Enid Zuckerman College of Public Health.

We welcome Dr. Benjamin Margolis of Albany Med. Dr. Margolis is a gynecologic oncologist who specializes in the medical and surgical management of ovarian, uterine, cervical and other gynecologic cancers. He also treats patients of all ages with pre-invasive conditions and complex gynecologic diseases that require surgery. Call at 2pm with your question. 800-348-2551. Ray Graf hosts.

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Campos discussed the clinical implications of findings from the gynecologic cancer cohorts of the phase 2 DESTINY-PanTumor02 trial (NCT04482309).

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Alessandro Santin to discuss Sacituzumab Govitecan (TROPiCS—03) in Advanced Endometrial Cancer. Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale University as Professor as of July 2008. Dr. Santin has more than 400 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy. Dr. Santin's clinical interests include the use of immunotherapy in ovarian, cervical and endometrial carcinoma patients with disease resistant/refractory to standard treatment, therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the development of personalized treatment modalities including monoclonal antibodies and antibody-drug-conjugates (ADC) against chemotherapy resistant gynecologic tumors. Highlights: In the TROPiCS-03 trial Sacituzumab Govitecan demonstrated encouraging clinical activity in recurrent endometrial cancer patients in progression after chemotherapy and immune check point inhibitors Sacituzumab Govitecan toxicity profile was manageable with only 5% of patients discontinuing treatment due to TRAEs TROP-2 protein was expressed in over 90% of endometrial cancer patients enrolled in the TROPiCS-03 trial and showed limited correlation with efficacy to Sacituzumab Govitecan

In today's episode, supported by Corcept Therapeutics, we had the pleasure of speaking with Premal Thaker, MD, MS, about the use of the selective glucocorticoid receptor modulator relacorilant (CORT125134) in patients with ovarian cancer. Dr Thaker is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, as well as the director of Gynecologic Oncology Clinical Research and the interim chief of the Division of Gynecologic Oncology at the School of Medicine at the Washington University in St. Louis and the Siteman Cancer Center in Missouri. In our exclusive interview, Dr Thaker discussed the rationale for combining relacorilant with nab-paclitaxel (Abraxane) in patients with platinum-resistant ovarian cancer, striking phase 2 data (NCT03776812) with this combination in this population, and what the future has in store regarding the phase 3 ROSELLA trial (NCT05257408).

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Rongyu Zang and Yulian Chen to discuss the SOC-1 trial. Dr. Rongyu Zang is the Director of the Department of Gynecologic Oncology, Fudan University Zhongshan Hospital, & Institute for Ovarian Cancer, Fudan University and is the Principal investigator of the SOC-1 and SUNNY trials. Dr. Yulian Chen is an Attending Physician at the Department of Gynecologic Oncology, Fudan University Zhongshan Hospital.   Highlights: The SOC-1 trial concluded that in patients with platinum-sensitive, relapsed ovarian cancer, surgery did not increase overall survival in the intention-to-treat population, but resulted in a prolongation of survival after adjustment of crossover. Surgery may provide an obviously higher proportion of long-term relapse-free survivors than chemotherapy alone. An active preoperative evaluation for all patients with platinum-sensitive first relapsed ovarian cancer is suggested in specialized centers.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Luis Chiva to discuss the Elikia project in the Democratic Republic of the Congo. Dr. Luis Chiva is the Head of Gynecology and Obstetrics and Director of Gynecologic Oncology at at Clínica Universidad de Navarra.   Highlights: Inspiration: Dr. Luis Chiva began the Elikia project in the DRC in 2016 after seeing the urgent need for cervical cancer screening and maternal health. Screening Approach: The project uses visual inspection with acetic acid, inspired by a successful model from India, to reduce cervical cancer mortality. Team and Challenges: A team of volunteers faces challenges like limited healthcare infrastructure and promoting preventive care. Sustainability: The project relies on donations and grants  to remain sustainable. Personal Impact: The work has profoundly influenced Dr. Chiva, renewing his commitment to humanitarian efforts.

The words “hormones” and “hot flashes” have been synonymous with menopause for decades. Now, more and more women have been speaking up and bringing this unique phase in a woman's life to the spotlight. And the medical community is paying attention.   Host:Johanna Gomez Guests:Alejandra Angel, M.D., OB/GYN at Baptist Health Baptist Hospital John P. Diaz, M.D., Chief of Gynecologic Oncology at Baptist Health Miami Cancer Institute